Clinical trial • Oncology
RP2 for Solid tumours
Clinical trial of RP2 for Solid tumours. 54 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Solid tumours
Key dates
- Initial CTIS Submission Date
- 02-05-2024
- First CTIS Authorization Date
- 08-05-2024
Trial design
Clinical trial across 3 sites in Spain.
- Target Sample Size
- 54
Eligibility
Recruits 54 No vulnerable populations selected; consent or assent handling not specified..
- Vulnerable Population
- No vulnerable populations selected; consent or assent handling not specified.
Recruitment
- Planned Sample Size
- 54
- Recruitment Window Months
- 16
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 54
Spain
- Earliest CTIS Part Ii Submission Date
- 27-03-2024
- Latest Decision Or Authorization Date
- 09-04-2026
- Processing Time Days
- 743
- Number Of Sites
- 3
- Number Of Participants
- 32
Sites
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Oncology
- Contact Person Name
- Irene Moreno Candilejo
- Contact Person Email
- irene.moreno@startmadrid.com
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Oncology
- Contact Person Name
- Andres Cervantes Ruiperez
- Contact Person Email
- andres.cervantes@uv.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncology
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
Sponsor
Primary sponsor
- Full Name
- Replimune Group Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- RP2
- Investigational Product Name
- PD1 Blockade
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID for Solid tumours
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer